LIPOPROTEIN(A) INHIBITS PLASMINOGEN ACTIVATION IN A TEMPLATE-DEPENDENT MANNER

被引:33
作者
EDELBERG, JM
PIZZO, SV
机构
[1] DUKE UNIV,DEPT PATHOL,BOX 3712,DURHAM,NC 27710
[2] DUKE UNIV,DEPT BIOCHEM,DURHAM,NC 27710
关键词
LIPOPROTEIN(A); HEPARIN; FIBRINOLYSIS AND LIPOPROTEINS; PLASMINOGEN ACTIVATION; PLASMINOGEN; TISSUE-TYPE PLASMINOGEN ACTIVATOR;
D O I
10.1097/00001721-199112000-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lipoprotein(a) [Lp(a)] is a low density lipoprotein whose plasma levels strongly correlate with the occurrence of atherosclerotic disease. Structural studies have demonstrated that Lp(a) contains two disulphide bonded subunits, one of which has structural similarity to plasminogen. This subunit, designated apo-lipoprotein(a), contains multiple repeat copies of a kringle homologous to kringle-4 of plasminogen, one copy of a kringle-5-like structure and a domain homologous to the catalytic light chain of plasmin. This subunit, however, lacks the site where plasminogen activators cleave plasminogen to generate the active proteinase. Recent studies demonstrate that Lp(a) competes with plasminogen for binding to endothelial cells and macrophages and thus prevents assembly of the fibrinolytic system on cell surfaces. Lp(a) also inhibits activation of plasminogen by streptokinase, urokinase-type plasminogen activator or tissue-type plasminogen activator (t-PA). Inhibition of plasminogen activation by t-PA requires the presence of a template on which activation occurs. This template can be either fibrin or heparin. This review considers the role of Lp(a) as an inhibitor of template-dependent activation of the fibrinolytic system.
引用
收藏
页码:759 / 764
页数:6
相关论文
共 63 条
[1]  
ALBERS JJ, 1977, J LIPID RES, V18, P331
[2]   INTERACTION OF HEPARIN WITH PLASMINOGEN ACTIVATORS AND PLASMINOGEN - EFFECTS ON THE ACTIVATION OF PLASMINOGEN [J].
ANDRADEGORDON, P ;
STRICKLAND, S .
BIOCHEMISTRY, 1986, 25 (14) :4033-4040
[3]  
ARMSTRONG VW, 1985, J LIPID RES, V26, P1314
[4]  
BARROWCLIFFE TW, 1989, HEPARIN RELATED POLY, P132
[5]  
BERG K, 1963, ACTA PATHOL MICROB S, V59, P166
[6]   IDENTIFICATION AND DISTRIBUTION OF FIBRINOGEN, FIBRIN, AND FIBRIN(OGEN) DEGRADATION PRODUCTS IN ATHEROSCLEROSIS - USE OF MONOCLONAL-ANTIBODIES [J].
BINI, A ;
FENOGLIO, JJ ;
MESATEJADA, R ;
KUDRYK, B ;
KAPLAN, KL .
ARTERIOSCLEROSIS, 1989, 9 (01) :109-121
[7]   QUANTITATIVE CHARACTERIZATION OF THE BINDING OF PLASMINOGEN TO INTACT FIBRIN CLOTS, LYSINE-SEPHAROSE, AND FIBRIN CLEAVED BY PLASMIN [J].
BOK, RA ;
MANGEL, WF .
BIOCHEMISTRY, 1985, 24 (13) :3279-3286
[8]  
BOSMA P, 1988, EUR J BIOCHEM, V173, P399
[9]   A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
SCIENCE, 1986, 232 (4746) :34-47
[10]   RECENT ADVANCES IN THE CHEMISTRY OF THE FIBRINOLYTIC SYSTEM [J].
CASTELLINO, FJ .
CHEMICAL REVIEWS, 1981, 81 (05) :431-446